237 related articles for article (PubMed ID: 23594731)
1. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.
Daniels-Wells TR; Helguera G; Leuchter RK; Quintero R; Kozman M; Rodríguez JA; Ortiz-Sánchez E; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
BMC Cancer; 2013 Apr; 13():195. PubMed ID: 23594731
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.
Daniels TR; Leuchter RK; Quintero R; Helguera G; Rodríguez JA; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
Cancer Immunol Immunother; 2012 Jul; 61(7):991-1003. PubMed ID: 22127364
[TBL] [Abstract][Full Text] [Related]
3. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
8. Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation.
Hong JY; Bae JH; Lee KE; Kim M; Kim MH; Kang HJ; Park EH; Yoo KS; Jeong SK; Kim KW; Kim KE; Sohn MH
Yonsei Med J; 2016 Nov; 57(6):1412-9. PubMed ID: 27593869
[TBL] [Abstract][Full Text] [Related]
9. FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.
Safaralizadeh R; Soheili ZS; Deezagi A; Pourpak Z; Samiei S; Moin M
Iran J Allergy Asthma Immunol; 2009 Dec; 8(4):177-83. PubMed ID: 20404387
[TBL] [Abstract][Full Text] [Related]
10. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
Karan D
Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
[TBL] [Abstract][Full Text] [Related]
11. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukemia (RBL) cell assay.
Dearman RJ; Skinner RA; Deakin N; Shaw D; Kimber I
Toxicology; 2005 Jan; 206(2):195-205. PubMed ID: 15588913
[TBL] [Abstract][Full Text] [Related]
13. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.
Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL
Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses.
Zellweger F; Gasser P; Brigger D; Buschor P; Vogel M; Eggel A
Allergy; 2017 Aug; 72(8):1174-1183. PubMed ID: 27997998
[TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
16. Blocking Allergic Reaction through Targeting Surface-Bound IgE with Low-Affinity Anti-IgE Antibodies.
Zhang K; Liu J; Truong T; Zukin E; Chen W; Saxon A
J Immunol; 2017 May; 198(10):3823-3834. PubMed ID: 28396318
[TBL] [Abstract][Full Text] [Related]
17. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
18. Histamine receptor H4 regulates mast cell degranulation and IgE induced FcεRI upregulation in murine bone marrow-derived mast cells.
Mirzahosseini A; Dalmadi B; Csutora P
Cell Immunol; 2013; 283(1-2):38-44. PubMed ID: 23850674
[TBL] [Abstract][Full Text] [Related]
19. IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity.
Starkl P; Marichal T; Gaudenzio N; Reber LL; Sibilano R; Tsai M; Galli SJ
J Allergy Clin Immunol; 2016 Jan; 137(1):246-257.e11. PubMed ID: 26410782
[TBL] [Abstract][Full Text] [Related]
20. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
